felodipine has been researched along with atenolol in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (12.50) | 18.7374 |
| 1990's | 8 (25.00) | 18.2507 |
| 2000's | 11 (34.38) | 29.6817 |
| 2010's | 9 (28.13) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Bruno-Blanch, L; Gálvez, J; García-Domenech, R | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Andrejak, M; Lesbre, JP; Morand, P; Raveau-Landon, C; Witchitz, S | 1 |
| Bengtsson-Hasselgren, B; Elmfeldt, D; Moberg, L; Rönn, O | 1 |
| Hannan, WJ; Muir, AL; Wathen, CG | 1 |
| Culling, W; Ruttley, MS; Sheridan, DJ | 1 |
| Goldberg, A; Sweet, C | 1 |
| Dunlay, MC; Goldberg, AI; Sweet, CS | 2 |
| Bergstrand, R; Eriksson, M; Lidman, K; Nyberg, G; Olofsson, B | 1 |
| Hoffmann, W; Hopmeier, P; Schernthaner, G; Schnack, C | 1 |
| Casati, C; Forlani, A; Lozza, G; Monopoli, A | 1 |
| Chern, MS; Lin, FC; Wu, D | 1 |
| Bossi, M; Tiberti, G | 1 |
| Anderson, A; Morgan, TO | 1 |
2 review(s) available for felodipine and atenolol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Calcium Channel Blockers; Controlled Clinical Trials as Topic; Cough; Dizziness; Dose-Response Relationship, Drug; Double-Blind Method; Fatigue; Felodipine; Female; Headache; Humans; Hypertension; Incidence; Losartan; Male; Middle Aged; Respiratory Tract Infections | 1995 |
7 trial(s) available for felodipine and atenolol
| Article | Year |
|---|---|
[Treatment of essential hypertension with felodipine or atenolol as first line therapy. Comparative double-blind randomized study].
Topics: Adult; Age Factors; Aged; Antihypertensive Agents; Atenolol; Double-Blind Method; Felodipine; Female; Humans; Hypertension; Male; Middle Aged; Nitrendipine; Random Allocation | 1989 |
Efficacy and safety of losartan.
Topics: Antihypertensive Agents; Atenolol; Biphenyl Compounds; Blood Pressure Monitoring, Ambulatory; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation; Enalapril; Felodipine; Humans; Hypertension; Imidazoles; Losartan; Placebos; Tetrazoles | 1995 |
Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Asthenia; Atenolol; Biphenyl Compounds; Cough; Dizziness; Double-Blind Method; Fatigue; Felodipine; Female; Headache; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Losartan; Male; Middle Aged; Placebos; Respiratory Tract Infections; Safety; Tetrazoles | 1995 |
Aiming for steady 24-hour plasma concentrations: a comparison of two calcium antagonist and beta-blocker combinations.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Chromatography, Gas; Chromatography, Liquid; Delayed-Action Preparations; Drug Combinations; Electrocardiography; Felodipine; Humans; Male; Metoprolol; Nifedipine | 1993 |
Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria.
Topics: Adrenergic beta-Antagonists; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood Pressure; Cohort Studies; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Felodipine; Female; Humans; Kidney; Male; Middle Aged; Prospective Studies; Ramipril; Vasodilator Agents | 1996 |
Comparison of clinical efficacy and adverse effects between extended-release felodipine and atenolol in patients with mild and moderate essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Calcium Channel Blockers; Felodipine; Female; Humans; Hypertension; Male; Middle Aged | 1997 |
Different drug classes have variable effects on blood pressure depending on the time of day.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Cross-Over Studies; Felodipine; Female; Heart Rate; Humans; Hydrochlorothiazide; Hypertension; Male; Perindopril | 2003 |
23 other study(ies) available for felodipine and atenolol
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.
Topics: Anticonvulsants; Computer Simulation; Databases, Factual; Discriminant Analysis; Drug Design; Molecular Structure; Quantitative Structure-Activity Relationship | 2003 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Haemodynamic effects and pharmacokinetics of felodipine at rest and during exercise in hypertensive patients treated with metoprolol or atenolol.
Topics: Aged; Atenolol; Blood Pressure; Calcium Channel Blockers; Exercise; Exercise Test; Felodipine; Female; Half-Life; Heart Rate; Hemodynamics; Humans; Hypertension; Male; Metoprolol; Middle Aged | 1989 |
Effects of felodipine on resistance and capacitance vessels in patients with essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Blood Vessels; Electrocardiography; Felodipine; Heart Rate; Humans; Hydralazine; Hypertension; Middle Aged; Nifedipine; Nitroglycerin; Stroke Volume; Vascular Resistance | 1985 |
Acute haemodynamic effects of felodipine during beta blockade in patients with coronary artery disease.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiac Catheterization; Cardiac Pacing, Artificial; Coronary Disease; Felodipine; Hemodynamics; Humans; Male; Middle Aged; Nifedipine; Stroke Volume; Vascular Resistance; Vasodilator Agents | 1984 |
Hemodynamic changes do not mediate the cardioprotection induced by the A1, adenosine receptor agonist CCPA in the rabbit.
Topics: Adenosine; Adenosine-5'-(N-ethylcarboxamide); Analysis of Variance; Animals; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Felodipine; Hemodynamics; Male; Myocardial Infarction; Purinergic P1 Receptor Agonists; Rabbits; Vasodilator Agents | 1997 |
[Stable angina pectoris: what is the role of calcium antagonists?].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Atenolol; Calcium Channel Blockers; Clinical Trials as Topic; Dihydropyridines; Diltiazem; Drug Therapy, Combination; Felodipine; Humans; Metoprolol; Multicenter Studies as Topic; Nifedipine; Randomized Controlled Trials as Topic; Verapamil | 1997 |